<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>C-11 choline: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">C-11 choline: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">C-11 choline: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F28332562"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F28332584"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Total injection volume per patient will vary based on patient body dimensions and the characteristics of the image acquisition system.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="821f6e2c-870c-4e76-bfc2-a79f53148282">Prostate imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate imaging:</b> IV: 10 to 20 mCi (370 to 740 MBq)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991961"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989299"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F28332586"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F29894169"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Local: Injection-site reaction</p></div>
<div class="block coi drugH1Div" id="F28332570"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F28332571"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Allergic reactions, including anaphylaxis, can occur. Treatment of hypersensitivity reactions should be available for immediate use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Radiation-emitting products may increase the risk for cancer, particularly in children. Use the smallest dose necessary and ensure safe handling to protect patients and healthcare workers.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concomitant drug therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Androgen-deprivation therapy: Concomitant use with androgen-deprivation therapy (eg, luteinizing hormone releasing analogs, antiandrogen drugs) may interfere with imaging.</p>
<p style="text-indent:-2em;margin-left:4em;">• Colchicine: Concomitant colchicine use may interfere with imaging; consider discontinuation of colchicine for 2 weeks prior to imaging.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not a replacement for histologic verification of recurrent prostate cancer. Patient should be fasting (at least 6 hours) prior to administration. Patients should be adequately hydrated 4 hours prior to imaging; instruct patients to void after each image session and frequently for 1 hour following completion of PET/CT scan.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risk for misinterpretation: Due to the high rate of false-positive or false-negative image interpretations, other appropriate tests should be done for confirmation of results. Tissue inflammation as well as prostatic hyperplasia have been associated with false-positive images; PSA levels &lt;2 ng/mL have been associated with poorer imaging results. Choline C 11 uptake is not specific for the prostate and may occur with other cancers (eg, lung, brain tumors).</p></div>
<div class="block foc drugH1Div" id="F28332629"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, solution: 148 to 1225 megabecquerels (4 to 33.1 mCi) per 1 mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F28332561"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block adm drugH1Div" id="F28332627"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as bolus through a peripheral venous catheter; obtain static emission images within 0 to 15 minutes after injection. Patient should be fasting (at least 6 hours) prior to administration to minimize the potential for dietary choline interference with radioactivity uptake in tissue. Patients should be adequately hydrated 4 hours prior to imaging; instruct patients to void after each image session and frequently for 1 hour following completion of PET/CT scan.</p></div>
<div class="block use drugH1Div" id="F28332565"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Prostate imaging:</b> Radiopharmaceutical imaging agent used in conjunction with positron emission tomography (PET) for patients with suspected prostate cancer recurrence and noninformative bone scintigraphy, computerized tomography (CT), or magnetic resonance imaging (MRI).</p></div>
<div class="block mst drugH1Div" id="F28332559"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F28407116"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F28407113"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antiandrogens: May diminish the therapeutic effect of Choline C 11.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May diminish the therapeutic effect of Choline C 11.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Choline C 11.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F28332567"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted. Not indicated for use in women.</p></div>
<div class="block brc drugH1Div" id="F28332569"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if choline C 11 is present in breast milk. Not indicated for use in women.</p></div>
<div class="block mop drugH1Div" id="F50872699"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of hypersensitivity.</p></div>
<div class="block pha drugH1Div" id="F28332576"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radiolabeled analog of choline, a precursor molecule essential for the biosynthesis of cell membrane phospholipids. Increased uptake of choline has been associated with cell proliferation and the transformation process that occurs in tumor cells.</p></div>
<div class="block phk drugH1Div" id="F28332578"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Within 5 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Activity retained &gt;30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Radioactivity also distributes to the pancreas, kidneys, liver, spleen, and colon</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: &lt;2% (1.5 hours postadministration)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Choline C 11 [prescribing information]. Noblesville, IN: Zevacor Molecular; January 2016.</div>
</li>
<li>
<div class="reference">
                  Parker JA, Daube-Witherspoon ME, Graham LS, et al. Procedure Guideline for General Imaging: 3.0. Society of Nuclear Medicine. 2004. http://interactive.snm.org/docs/General_Imaging_v3.0.pdf.</div>
</li>
<li>
<div class="reference">
                  U.S. Nuclear Regulatory Commission (USNRC). Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials. 1997.</div>
</li></ol></div><div id="topicVersionRevision">Topic 101769 Version 27.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
